Clinical trials: Hepatitis C, completed
Hepatitis C, Swallowing Disorder
Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.
Epclusa® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide analogue) 400 mg and the NS5A inhibitor…
- Trial name
- COPA (NCT03513393)
- Testing
- velpatasvir
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Genotype 1 Chronic Hepatitis C, Treatment Naive
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with Peg-IFN-alfa-2a and ribavirin in treatment-naïve participants with chronic HCV genotype 1…
- Trial name
- NCT01241760
- Testing
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Where
- 99 sites in United States, Australia and 11 more
- Volunteers
- 744 people
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatitis C
Pilot HCV Direct Acting Antiviral Therapy and Metabolism
There is compelling data supporting the pursuit of research into the effects of HCV antivirals on metabolic homeostasis. As a further rationale and justification, the experience with HIV antiretrovirals has clearly demonstrated…
- Trial name
- 3D (NCT02734173)
- Testing
- ABT450r-ABT267-ABT333 +/- Ribavirin
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Ottawa Hospital Research Institute
Hepatitis c
Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection
Two Groups of Genotype 4 HCV Patients will participate through open-label randomized Study comparing Sofosbuvir tablet Plus Ribavirin tablet (Part A) versus single Dose (2 tablets) of EHCV containing Sofosbuvir, Ribavirin, and…
- Trial name
- NCT02483156
- Testing
- Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg, Sofosbuvir tablet (SOF) 400 mg - once daily, Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Egyptian Liver Hospital
Hepatitis C, Cirrhosis
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
- Conditions
- Hepatitis C, Cirrhosis, Fibrosis
- Trial name
- NCT00252642
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Hepatitis C, Chronic, Heart Failure
Hepatitis C Virus(HCV) Heart and Lung Study
This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.
- Conditions
- Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
- Trial name
- NCT02858180
- Testing
- Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
HCV
Xpert Hepatitis-C Virus (HCV) Test on the GeneXpert Xpress System
A multi-site prospective, all comers study that was conducted at geographically diverse locations in the United States.
- Trial name
- NCT06508996
- Testing
- Xpert HCV
- Where
- United States
- Volunteers
- 1,012 people
- Sponsor
- Cepheid
Hepatitis C, Genotype 1
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
- Trial name
- NCT01471574
- Testing
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 549 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)
This is a randomized, parallel-group, placebo-controlled, multi-site, multinational, double-blind followed by open label period, Phase 3 trial of 100 mg of grazoprevir (MK-5172) in combination with 50 mg of elbasvir (MK-8742)…
- Trial name
- NCT02251990
- Testing
- Grazoprevir/Elbasvir
- Volunteers
- 489 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis, Hepatitis B
Crowdsourcing to Promote HBV and HCV Testing in China
This is an online randomized controlled trial (RCT) comparing men who have sex with men (MSM) exposed to a crowdsourced intervention to MSM who did not receive the intervention to determine the effect on Hepatitis B Virus (HBV)…
- Conditions
- Hepatitis, Hepatitis B, Hepatitis C
- Trial name
- NCT03482388
- Testing
- Crowdsourced materials, Control
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C Virus
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with…
- Trial name
- HEPCAT (NCT01170962)
- Testing
- BMS-790052, peginterferon alfa-2a, ribavirin
- Where
- 72 sites in United States, Argentina and 9 more
- Volunteers
- 512 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
The study aimed at evaluating whether current 24 weeks length of combination treatment is appropriate or not for patients with HCV genotype 3 infection.
- Trial name
- genotype-3 (NCT01121705)
- Testing
- Peg Interferon alpha2b + Ribavirin
- Where
- 8 sites in Italy
- Volunteers
- 360 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection
The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.
- Trial name
- NCT02068222
- Testing
- ABT-450/ritonavir (r), ABT-530, Ribavirin (RBV)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Chronic Hepatitis C, Hepatitis, Viral, Human
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
The purpose of this study is to assess the safety and efficacy of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT00230854
- Testing
- EMZ702
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- OPKO Health, Inc.
Hepatitis C, Renal Cell Carcinoma
Association Between Hepatitis C Infection and Renal Cell Carcinoma
The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered…
- Conditions
- Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT01405183
- Testing
- Hepatitis C testing
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Henry Ford Health System
Chronic Hepatitis C
Natural History of Hepatitis C in Patients With Normal Liver Tests
The Major goals of this project was to assess the natural history of disease in chronic hepatitis C patients with normal ALT and to determine the virologic and host factors associated with disease severity.
- Trial name
- NCT00187473
- Testing
- liver biopsy
- Volunteers
- 92 people
- Sponsor
- University of California, San Francisco
Meningococcal Meninigitis, Serogroup C
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
The primary aim of the study is to show that the antibody response to hepatitis B, acellular pertussis toxin and inactivated poliovirus antigens after the 4th vaccination with Hexavac® is not influenced by the concomitant…
- Trial name
- NCT00161941
- Where
- 11 sites in Austria, Germany
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C Virus (HCV)
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet…
- Trial name
- NCT03212521
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 42 sites in United States, Bulgaria and 8 more
- Volunteers
- 230 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy
Integrated Treatment of Hepatitis C Virus Infection
INTRO-HCV is a multicentre randomised controlled clinical trial that will compare the efficacy of integrated treatment of chronic hepatitis C virus infection (HCV) within medically assisted rehabilitation (MAR) clinics providing…
- Trial name
- INTRO-HCV (NCT03155906)
- Testing
- Health care delivery
- Where
- 2 sites in Norway
- Volunteers
- 298 people
- Sponsor
- Haukeland University Hospital
Hepatitis C
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
The purposes of the PLUS study were to confirm the safety and tolerability of two doses of LocteronTM (320 ug and 640 ug) dosed over four weeks in patients who had failed prior anti-HCV therapies (Panels A and B), and then to…
- Trial name
- PLUS (NCT00593151)
- Testing
- Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Biolex Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.